HAE HAEMONETICS CORP

NYSE haemonetics.com


$ 49.35 $ 1.19 (2.45 %)    

Thursday, 16-Oct-2025 16:04:44 EDT
QQQ $ 590.97 $ 0.00 (0 %)
DIA $ 454.47 $ 0.00 (0 %)
SPY $ 652.21 $ 0.00 (0 %)
TLT $ 91.50 $ 0.00 (0 %)
GLD $ 400.20 $ 0.00 (0 %)
$ 49.77
$ 48.63
$ 48.50 x 5
$ 50.54 x 10
-- - --
$ 47.32 - $ 94.99
1,043,010
na
2.4B
$ 0.75
$ 14.68
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-28-2025 10-Q
2 05-21-2025 03-29-2025 10-K
3 02-06-2025 12-28-2024 10-Q
4 11-07-2024 09-28-2024 10-Q
5 08-08-2024 06-29-2024 10-Q
6 05-20-2024 03-30-2024 10-K
7 02-08-2024 12-30-2023 10-Q
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 07-01-2023 10-Q
10 05-22-2023 04-01-2023 10-K
11 02-07-2023 12-31-2022 10-Q
12 11-08-2022 10-01-2022 10-Q
13 08-10-2022 07-02-2022 10-Q
14 05-25-2022 04-02-2022 10-K
15 02-08-2022 01-01-2022 10-Q
16 11-09-2021 10-02-2021 10-Q
17 08-11-2021 07-03-2021 10-Q
18 05-26-2021 04-03-2021 10-K
19 02-02-2021 12-26-2020 10-Q
20 11-04-2020 09-26-2020 10-Q
21 08-04-2020 06-27-2020 10-Q
22 05-20-2020 03-28-2020 10-K
23 02-04-2020 12-28-2019 10-Q
24 11-01-2019 09-28-2019 10-Q
25 08-06-2019 06-29-2019 10-Q
26 05-22-2019 03-30-2019 10-K
27 02-05-2019 12-29-2018 10-Q
28 11-06-2018 09-29-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-23-2018 03-31-2018 10-K
31 02-06-2018 12-30-2017 10-Q
32 11-07-2017 09-30-2017 10-Q
33 08-07-2017 07-01-2017 10-Q
34 05-24-2017 04-01-2017 10-K
35 02-06-2017 12-31-2016 10-Q
36 11-07-2016 10-01-2016 10-Q
37 08-01-2016 07-02-2016 10-Q
38 06-01-2016 04-02-2016 10-K
39 02-02-2016 12-26-2015 10-Q
40 11-04-2015 09-26-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-buy-on-haemonetics-lowers-price-target-to-64

Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Buy and lowers the price target from $78 to $64.

 barrington-research-maintains-outperform-on-haemonetics-maintains-86-price-target

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $86 price target.

 raymond-james-downgrades-haemonetics-to-outperform-lowers-price-target-to-78

Raymond James analyst Andrew Cooper downgrades Haemonetics (NYSE:HAE) from Strong Buy to Outperform and lowers the price tar...

 barrington-research-maintains-outperform-on-haemonetics-lowers-price-target-to-86

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target f...

 mizuho-maintains-outperform-on-haemonetics-lowers-price-target-to-70

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $90 to $70.

 jp-morgan-downgrades-haemonetics-to-neutral-lowers-price-target-to-62

JP Morgan analyst Rohin Patel downgrades Haemonetics (NYSE:HAE) from Overweight to Neutral and lowers the price target from ...

 needham-maintains-buy-on-haemonetics-lowers-price-target-to-68

Needham analyst Mike Matson maintains Haemonetics (NYSE:HAE) with a Buy and lowers the price target from $84 to $68.

 haemonetics-affirms-fy2026-adj-eps-guidance-of-470-500-vs-487-est

Haemonetics (NYSE:HAE) affirms FY2026 Adj EPS guidance from $4.70-$5.00 to $4.70-$5.00 vs $4.87 analyst estimate..

 haemonetics-q1-adj-eps-110-beats-102-estimate-sales-321394m-beat-305115m-estimate

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.02 by 7.9...

 barrington-research-maintains-outperform-on-haemonetics-maintains-95-price-target

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $95 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION